{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T01:41:44Z","timestamp":1787708504710,"version":"build-2784847793"},"reference-count":40,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triplet regimens, such as lenalidomide, bortezomib, and dexamethasone (RVd) or thalidomide, bortezomib, and dexamethasone (VTd), are standard induction therapies for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The addition of daratumumab to RVd and VTd has been investigated in the GRIFFIN and CASSIOPEIA trials, respectively, resulting in improvement in the rate of minimal residual disease (MRD) negativity. In this study, we conducted a cost-effectiveness analysis with a 10-year time horizon to compare first-line and second-line use of daratumumab for transplant-eligible patients with NDMM. Because long-term follow-up data for these clinical trials are not yet available, we developed a Markov model that uses MRD status to predict progression-free survival. Daratumumab was used either in the first-line setting in combination with RVd or VTd or in the second-line setting with carfilzomib plus dexamethasone (Kd). Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios were calculated from a Japanese and US payer perspective. In the Japanese analysis, D-RVd showed higher QALYs (5.43 vs 5.18) and lower costs (\u00a564\u2009479,793 vs \u00a571\u2009\u2009287\u2009569) compared with RVd, and D-VTd showed higher QALYs (5.67 vs 5.42) and lower costs (\u00a543\u2009\u2009600\u2009310 vs \u00a549\u2009471,941) compared with VTd. Similarly, the US analysis demonstrated dominance of a strategy incorporating daratumumab in first-line treatment regimens. Given that overall costs are reduced and outcomes are improved when daratumumab is used as part of a first-line regimen, the economic analysis indicates that addition of daratumumab to first-line RVd and VTd regimens is a dominant strategy compared with reserving its use for the second-line setting.<\/jats:p>","DOI":"10.1182\/blood.2021015220","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T19:05:32Z","timestamp":1652814332000},"page":"594-607","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-8414","authenticated-orcid":false,"given":"Chihiro","family":"Yamamoto","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Koyama","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Fukui","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Murahashi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2262-6699","authenticated-orcid":false,"given":"Hirotomo","family":"Nakashima","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Ito","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-2955","authenticated-orcid":false,"given":"Takashi","family":"Nagayama","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-8189","authenticated-orcid":false,"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuzu","family":"Ueda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-4224","authenticated-orcid":false,"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"},{"name":"2Division of Cell Transplantation and Transfusion, Jichi Medical University, Shimotsuke, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2022081115222974200_B1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2022081115222974200_B2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2020003642","article-title":"Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN","volume":"5","author":"Voorhees","year":"2021","journal-title":"Blood Adv."},{"issue":"12","key":"2022081115222974200_B3","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol."},{"issue":"10","key":"2022081115222974200_B4","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"2022081115222974200_B5","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-149024","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance","volume":"138","author":"Laubach","year":"2021","journal-title":"Blood."},{"issue":"1","key":"2022081115222974200_B6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia."},{"issue":"8","key":"2022081115222974200_B7","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"23","key":"2022081115222974200_B8","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022081115222974200_B9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"issue":"14","key":"2022081115222974200_B10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med."},{"issue":"23","key":"2022081115222974200_B11","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood."},{"issue":"12","key":"2022081115222974200_B12","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia."},{"issue":"10","key":"2022081115222974200_B13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.20.01849","article-title":"Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma","volume":"39","author":"Patel","year":"2021","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022081115222974200_B14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"2022081115222974200_B15","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther."},{"issue":"1","key":"2022081115222974200_B16","first-page":"29","article-title":"Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States","volume":"24","author":"Carlson","year":"2018","journal-title":"J Manag Care Spec Pharm."},{"issue":"3","key":"2022081115222974200_B17","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1002\/ajh.25372","article-title":"Daratumumab vs pomalidomide for the treatment of relapsed\/refractory multiple myeloma: a cost-effectiveness analysis","volume":"94","author":"Gong","year":"2019","journal-title":"Am J Hematol."},{"issue":"2","key":"2022081115222974200_B18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.clinthera.2019.12.007","article-title":"Economic evaluation of adding daratumumab to a regimen of bortezomib\u00a0+ dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR","volume":"42","author":"Zeng","year":"2020","journal-title":"Clin Ther."},{"issue":"7","key":"2022081115222974200_B19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","article-title":"Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Zhang","year":"2018","journal-title":"Clin Ther."},{"issue":"10245","key":"2022081115222974200_B20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet."},{"issue":"2","key":"2022081115222974200_B21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med."},{"issue":"19","key":"2022081115222974200_B22","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med."},{"issue":"11","key":"2022081115222974200_B23","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol."},{"issue":"6","key":"2022081115222974200_B24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment [published correction appears in Blood. 2016;127(26):3460]","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood."},{"issue":"2","key":"2022081115222974200_B25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol."},{"issue":"10","key":"2022081115222974200_B26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA."},{"issue":"10","key":"2022081115222974200_B27","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2015.05.013","article-title":"Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"2022081115222974200_B28","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41409-019-0574-5","article-title":"Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells","volume":"54","author":"Olry de Labry Lima","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"2022081115222974200_B29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hec.3871","article-title":"Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data","volume":"28","author":"Hatswell","year":"2019","journal-title":"Health Econ."},{"issue":"2","key":"2022081115222974200_B30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/10428194.2020.1832672","article-title":"Efficacy and safety of weekly carfilzomib (70\u2009mg\/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies","volume":"62","author":"Leleu","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"10214","key":"2022081115222974200_B31","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet."},{"issue":"6","key":"2022081115222974200_B32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"2022081115222974200_B33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"2022081115222974200_B34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"2022081115222974200_B35","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia."},{"key":"2022081115222974200_B36","doi-asserted-by":"crossref","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ."},{"key":"2022081115222974200_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow up analysis of the IFM 2009 Trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood."},{"issue":"10292","key":"2022081115222974200_B38","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet."},{"issue":"8","key":"2022081115222974200_B39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"issue":"10297","key":"2022081115222974200_B40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/6\/594\/1912893\/bloodbld2021015220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/6\/594\/1912893\/bloodbld2021015220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T19:10:18Z","timestamp":1700593818000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/6\/594\/485281\/Daratumumab-in-first-line-therapy-is-cost"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021015220","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}